QuickLinks -- Click here to rapidly navigate through this documentUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | | January 19, 2006 (January 19, 2006) |
Endo Pharmaceuticals Holdings Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation) | | 001-15989
(Commission
File Number) | | 13-4022871
(I.R.S. Employer
Identification No.) |
100 Endo Boulevard, Chadds Ford, PA
(Address of principal executive offices) |
|
19317
(Zip Code) |
Registrant's telephone number, including area code (610) 558-9800
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On January 19, 2006, Endo Pharmaceuticals Holdings Inc. filed an automatically effective shelf registration statement on Form S-3 with the Securities and Exchange Commission allowing for delayed offerings pursuant to Rule 415 of the General Rules and Regulations under the Securities Act of 1933, as amended, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
- (a)
- Financial Statements of Business Acquired.
Not applicable.
- (b)
- Pro Forma Financial Information.
Not applicable.
- (c)
- Exhibits.
Exhibit Number
| | Description
|
|---|
| 99.1 | | Registration Statement on Form S-3, dated January 19, 2006 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | | ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant) |
|
|
By: |
/s/ CAROLINE B. MANOGUE
Name: Caroline B. Manogue
Title: Executive Vice President, Chief Legal Officer & Secretary |
Dated: January 19, 2006
INDEX TO EXHIBITS
Exhibit No.
| | Description
|
|---|
| 99.1 | | Registration Statement on Form S-3, dated January 19, 2006 |
QuickLinks
FORM 8-KEndo Pharmaceuticals Holdings Inc.SIGNATURESINDEX TO EXHIBITS
